Skip to main content
Log in

Die akuten hepatischen Porphyrien in der Notfall- und Intensivmedizin

Attacks of acute porphyrias and their emergency management

  • ÜBERSICHT
  • Published:
Intensivmedizin und Notfallmedizin

Summary

The acute porphyrias are four rare disorders which are characterized by an inborn enzymatic error of the biosynthesis of heme. In Europe, acute intermittent porphyria represents the main subtype of the acute porphyrias, whereas variegate porphyria and hereditary coproporphyria are less common. Concerning 5-aminolevulinic-acid-dehydratase-deficient porphyria less than ten cases have been described worldwide. Normally, acute porphyrias remain clinically inapparent during the whole lifetime. Under certain environmental circumstances (e. g., pharmacological, endocrine or nutritional factors), they might produce attacks with varying gastrointestinal, neurological and/or psychiatric symptoms. Such an attack can progress into a life-threatening crisis with quadraparesis, respiratory arrest, SIADH, hyponatriemia, seizures and/or cardiac arrhythmia. Each attack of an acute porphyria can be definitely diagnosed by urine analysis of porphobilinogen and 5-aminolaevulinic acid, which however needs initial clinical suspicion. Early treatment contributes to—but not necessarily guarantees—a rapid remission of the attack. The treatment comprises avoidance of any precipitating factor and administration of heme arginate or high-dose glucose infusions which interrupt the dysregulated hepatic heme biosynthesis.

Zusammenfassung

Die akuten Porphyrien umfassen eine Gruppe von vier seltenen Stoffwechselerkrankungen mit einem angeborenen Defekt innerhalb der achtstufigen Hämbiosynthese. In Europa ist der häufigste Subtyp die Akute Intermittierende Porphyrie. Die Porphyria Variegata und die Hereditäre Koproporphyrie sind weitaus seltener. Zur 5-Aminolävulinsäure-Dehyratase-Defizienz-Porphyrie existieren weltweit weniger als zehn Fallberichte. In der Regel bleiben die akuten Porphyrien zeitlebens klinisch inapparent. Nur unter bestimmten Umständen (z. B. Medikamente, endokrine Faktoren, Mangelernährung oder Nikotinabusus) treten sie in Form sogenannter Attacken mit dann schwersten Bauchschmerzen und/oder neurologischen bzw. psychiatrischen Symptomen in Erscheinung. Das klinische Bild der porphyrischen Attacke ist variabel; gefürchtete Komplikationen sind Tetraparese unter Einbeziehung der Atemmuskulatur, SIADH mit Hyponatriämie und Krampfanfälle oder kardiale Arrhythmien. Eine porphyrische Attacke lässt sich anhand einer Urinanalyse auf Porphobilinogen und 5-Aminolävulinsäure diagnostisch bestätigen oder ausschließen; dies setzt jedoch einen aktiven klinischen Anfangsverdacht voraus. Die umgehende Einleitung einer kausalen Therapie trägt zur frühzeitigen Remission einer Attacke bei, sie ist jedoch keine Garantie dafür. Therapiemaßnahmen umfassen neben dem sofortigen Absetzen jeglicher potenziell porphyrinogener Faktoren die Gabe von Hämarginat mit ggf. zusätzlich hochdosierter Glukose, wodurch die fehlregulierte hepatische Hämbiosynthese durchbrochen wird.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Allen KR, Rushworth PA, Degg TJ, Barth JH (1997) Measurement of urinary porphobilinogen and porphyrins: preliminary data from a pilot QA scheme. Ann Clin Biochem 34:553–555

    PubMed  Google Scholar 

  2. Anderson KE, Sassa S, Bishop DF, Desnik RJ (2001) Disorders of Heme Biosynthesis: X-Linked Sideroblastic Anemia and the Porphyrias. In: Sriver CR, Beaudet AL, Sly WS, Vale D (Hrsg) The Metabolic and Molecular Bases of Inherited Disease. MacGraw-Hill, New York, S 2991–3062

  3. Anderson KE, Spitz IM, Bardin CW, Kappas A (1990) A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med 150:1469–1474

    Article  CAS  PubMed  Google Scholar 

  4. Andersson C, Nilsson A, Backstrom T (2002) Atypical attack of acute intermittent porphyria–paresis but no abdominal pain. J Intern Med 252:265–270

    Article  CAS  PubMed  Google Scholar 

  5. Atsmon A, Blum I, Fischl J (1972) Treatment of an acute attack of porphyria variegata with propranolol. S Afr Med J 46:311–314

    CAS  PubMed  Google Scholar 

  6. Badminton MN, Elder GH (2002) Management of acute and cutaneous porphyrias. Int J Clin Pract 56:272–278

    CAS  PubMed  Google Scholar 

  7. Barohn RJ, Sanchez JA, Anderson KE (1994) Acute peripheral neuropathy due to hereditary coproporphyria. Muscle Nerve 17:793–799

    CAS  PubMed  Google Scholar 

  8. Beattie AD, Moore MR, Goldberg A, Ward RL (1973) Acute intermittent porphyria: response of tachycardia and hypertension to propranolol. Br Med J 3:257–260

    CAS  PubMed  Google Scholar 

  9. Bengtsson NO, Hardell L (1986) Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer 54:115–117

    CAS  PubMed  Google Scholar 

  10. Blom H, Andersson C, Olofsson BO, Bjerle P, Wiklund U, Lithner F (1996) Assessment of autonomic nerve function in acute intermittent porphyria; a study based on spectral analysis of heart rate variability. J Intern Med 240:73–79

    Article  CAS  PubMed  Google Scholar 

  11. Bonkovsky HL, Barnard GF (1998) Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis 18:57–65

    CAS  PubMed  Google Scholar 

  12. Bonkowsky HL, Sinclair PR, Emery S, Sinclair JF (1980) Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. Neurology 30:588–592

    CAS  PubMed  Google Scholar 

  13. Bonkowsky HL, Tschudy DP (1974) Hazard of propranolol in treatment of acute prophyria. Br Med J 4:47–48

    CAS  Google Scholar 

  14. Brodie MJ, Thompson GG, Moore MR, Beattie AD, Goldberg A (1977) Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood. Q J Med 46:229–241

    CAS  PubMed  Google Scholar 

  15. Burgovne K, Swartz R, Ananth J (1995) Porphyria: reexamination of psychiatric implications. Psychother Psychosom 64:121–130

    CAS  PubMed  Google Scholar 

  16. Buttery JE, Carrera AM, Pannall PR (1990) Reliability of the porphobilinogen screening assay. Pathology 22:197–198

    CAS  PubMed  Google Scholar 

  17. Bylesjo I, Forsgren L, Lithner F, Boman K (1996) Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia 37:230–235

    CAS  PubMed  Google Scholar 

  18. Church SE, McColl KE, Moore MR, Youngs GR (1992) Hypertension and renal impairment as complications of acute porphyria. Nephrol Dial Transplant 7:986–990

    CAS  PubMed  Google Scholar 

  19. Crimlisk HL (1997) The little imitator-porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 62:319–328

    CAS  PubMed  Google Scholar 

  20. De Block CE, Leeuw IH, Gaal LF (1999) Premenstrual attacks of acute intermittent porphyria: hormonal and metabolic aspects—a case report. Eur J Endocrinol 141:50–54

    CAS  PubMed  Google Scholar 

  21. Deacon AC, Elder GH (2001) ACP Best Practice No 165: front line tests for the investigation of suspected porphyria. J Clin Pathol 54:500–507

    Article  CAS  PubMed  Google Scholar 

  22. Doss M, Verspohl F (1981) The „glucose effect“ in acute hepatic porphyrias and in experimental porphyria. Klin Wochenschr 59:727–735

    CAS  PubMed  Google Scholar 

  23. Doss MO (1997) Hepatische Porphyrien. Med Klin (München) 92:745–746

    CAS  PubMed  Google Scholar 

  24. Doss MO (2000) Porphyrie. In: Thomas L (Hrsg) Labor und Diagnose—Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. TH-Books Verlagsgesellschaft, Frankfurt, S 458–474

  25. Doss MO (2004) Porphyrien und Porphyrinstoffwechselstörungen. In: Classen M, Diehl V, Kochsiek K, Schmiegel W (Hrsg) Innere Medizin. Urban & Fischer, München Jena, S 1580–1593

  26. Doss MO, Stölzel U, Doss M (2003) Porphyrien, akute hepatische—Arzneistoffe bei akuten hepatischen Porphyrien und Empfehlungen zur Anästhesie. In: Rote-Liste-Service GmbH Hrsg) Rote Liste 2003. Editio Cantor Verlag, Aulendorf, S 493–494

  27. Douer D, Weinberger A, Pinkhas J, Atsmon A (1978) Treatment of acute intermittent porphyria with large doses of propranolol. JAMA 240:766–768

    Article  CAS  PubMed  Google Scholar 

  28. Elder GH, Hift RJ (2001) Treatment of acute porphyria. Hosp Med 62:422–425

    CAS  PubMed  Google Scholar 

  29. Elder GH, Hift RJ, Meissner PN (1997) The acute porphyrias. Lancet 349:1613–1617

    Article  CAS  PubMed  Google Scholar 

  30. Goldberg A (1959) Acute intermittent porphyria: a study of 50 cases. Q J Med 28:183–209

    CAS  PubMed  Google Scholar 

  31. Gonzalez-Arriaza HL, Bostwick JM (2003) Acute porphyrias: a case report and review. Am J Psychiatry 160:450–459

    Article  PubMed  Google Scholar 

  32. Gordon N (1999) The acute porphyrias. Brain Dev 21:373–377

    Article  CAS  PubMed  Google Scholar 

  33. Hahn M, Gildemeister OS, Krauss GL, Pepe JA, Lambrecht RW, Donohue S, Bonkovsky HL (1997) Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology 49:97–106

    CAS  PubMed  Google Scholar 

  34. Herrick AL, McColl KE, Moore MR, Cook A, Goldberg A (1989) Controlled trial of haem arginate in acute hepatic porphyria. Lancet 1:1295–1297

    Article  CAS  PubMed  Google Scholar 

  35. Hindmarsh JT, Oliveras L, Greenway DC (1999) Biochemical differentiation of the porphyrias. Clin Biochem 32:609–619

    Article  CAS  PubMed  Google Scholar 

  36. Jeans JB, Savik K, Gross CR, Weimer MK, Bossenmaier IC, Pierach CA, Bloomer JR (1996) Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet 65:269–273

    Article  CAS  PubMed  Google Scholar 

  37. Kalman DR, Bonkovsky HL (1998) Management of acute attacks in the porphyrias. Clin Dermatol 16:299–306

    Article  CAS  PubMed  Google Scholar 

  38. Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 71:1–13

    CAS  PubMed  Google Scholar 

  39. Kauppinen R, von und zu Fraunberg M (2002) Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 48:1891–1900

    CAS  PubMed  Google Scholar 

  40. Kirsch RE, Meissner PN, Hift RJ (1998) Variegate porphyria. Semin Liver Dis 18:33–41

    CAS  PubMed  Google Scholar 

  41. Krauss GL, Simmons-O’Brien E, Campbell M (1995) Successful treatment of seizures and porphyria with gabapentin. Neurology 45:594–595

    CAS  PubMed  Google Scholar 

  42. Kühnel A, Gross U, Jacob K, Doss MO (1999) Studies on coproporphyrin isomers in urine and feces in the porphyrias. Clin Chim Acta 282:45–58

    Article  PubMed  Google Scholar 

  43. Kunitz O, Frank J (2001) Anästhesiologisches Management bei Patienten mit akuten Porphyrien. Anaesthesist 50:957–966

    Article  CAS  PubMed  Google Scholar 

  44. Kupferschmidt H, Bont A, Schnorf H, Landis T, Walter E, Peter J, Krahenbuhl S, Meier PJ (1995) Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med 123:598–600

    CAS  PubMed  Google Scholar 

  45. Larson AW, Wasserstrom WR, Felsher BF, Chih JC (1978) Posttraumatic epilepsy and acute intermittent porphyria: effects of phenytoin, carbamazepine, and clonazepam. Neurology 28:824–828

    CAS  PubMed  Google Scholar 

  46. Leger JM, Salachas F (2001) Diagnosis of motor neuropathy. Eur J Neurol 8:201–208

    Article  CAS  PubMed  Google Scholar 

  47. Lip GY, McColl KE, Goldberg A, Moore MR (1991) Smoking and recurrent attacks of acute intermittent porphyria. Br Med J 302:507

    CAS  Google Scholar 

  48. Lip GY, McColl KE, Moore MR (1993) The acute porphyrias. Br J Clin Pract 47:38–43

    CAS  PubMed  Google Scholar 

  49. Mattern SE, Tefferi A (1999) Acute porphyria: the cost of suspicion. Am J Med 107:621–623

    Article  CAS  PubMed  Google Scholar 

  50. Merritt JE, Loening KL (1980) IUPAC-IUB joint commission on biochemical nomenclature (JCBN). Nomenclature of tetrapyrroles. Recommendations 1978. Eur J Biochem 108:1–30

    CAS  PubMed  Google Scholar 

  51. Meyer UA, Schuurmans MM, Lindberg RL (1998) Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 18:43–52

    CAS  PubMed  Google Scholar 

  52. Meyer UA, Strand LJ, Doss M, Rees AC, Marver HS (1972) Intermittent acute porphyria–demonstration of a genetic defect in porphobilinogen metabolism. N Engl J Med 286:1277–1282

    CAS  PubMed  Google Scholar 

  53. Moore MR (1998) The biochemistry of heme synthesis in porphyria and in the porphyrinurias. Clin Dermatol 16:203–223

    Article  CAS  PubMed  Google Scholar 

  54. Muehlenberg K, Nauck F (1995) Patient-controlled analgesia with pethidine in acute intermittent porphyria. Dtsch Med Wochenschr 120:1454

    CAS  PubMed  Google Scholar 

  55. Mustajoki P (1980) Variegate porphyria. Twelve years’ experience in Finland. Q J Med 49:191–203

    CAS  PubMed  Google Scholar 

  56. Mustajoki P, Nordmann Y (1993) Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 153:2004–2008

    Article  CAS  PubMed  Google Scholar 

  57. Nordmann Y, Puy H (2002) Human hereditary hepatic porphyrias. Clin Chim Acta 325:17–37

    Article  CAS  PubMed  Google Scholar 

  58. Nordmann Y, Puy H, Da S, V, Simonin S, Robreau AM, Bonaiti C, Phung LN, Deybach JC (1997) Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med 242:213–217

    Article  CAS  PubMed  Google Scholar 

  59. Nordmann Y, Puy H, Deybach JC (1999) The porphyrias. J Hepatol 30 S1:12–16

    PubMed  Google Scholar 

  60. Periasamy V, al Shubaili A, Girsh Y (2002) Diagnostic dilemmas in acute intermittent porphyria. A case report. Med Princ Pract 11:108–111

    Article  PubMed  Google Scholar 

  61. Petrides P (1997) Die akute intermittierende Porphyrie. Dtsch Ärztebl 50:3407–3412

    Google Scholar 

  62. Poblete GP, Kunitz O, Wolff C, Frank J (2001) Diagnosis and treatment of the acute porphyrias: an interdisciplinary challenge. Skin Pharmacol Appl Skin Physiol 14:393–400

    Article  PubMed  Google Scholar 

  63. Rey MJ, Schulz P, Costa C, Dick P, Tissot R (1989) Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 4:95–104

    CAS  PubMed  Google Scholar 

  64. Sadeh M, Blatt I, Martonovits G, Karni A, Goldhammer Y (1991) Treatment of porphyric convulsions with magnesium sulfate. Epilepsia 32:712–715

    CAS  PubMed  Google Scholar 

  65. Santosh PJ, Malhotra S (1994) Varied psychiatric manifestations of acute intermittent porphyria. Biol Psychiatry 36:744–747

    Article  CAS  PubMed  Google Scholar 

  66. Sassa S, Kappas A (2000) Molecular aspects of the inherited porphyrias. J Intern Med 247:169–178

    Article  CAS  PubMed  Google Scholar 

  67. Stein JA, Tschudy DP (1970) Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine (Baltimore) 49:1–16

    CAS  PubMed  Google Scholar 

  68. Suarez JI, Cohen ML, Larkin J, Kernich CA, Hricik DE, Daroff RB (1997) Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature. Neurology 48:1678–1683

    CAS  PubMed  Google Scholar 

  69. Tenhunen R, Mustajoki P (1998) Acute porphyria: treatment with heme. Semin Liver Dis 18:53–55

    CAS  PubMed  Google Scholar 

  70. Thadani H, Deacon A, Peters T (2000) Diagnosis and management of porphyria. Br Med J 320:1647–1651

    Article  CAS  Google Scholar 

  71. Thunell S (2000) Porphyrins, porphyrin metabolism and porphyrias. I. Update. Scand J Clin Lab Invest 60:509–540

    Article  CAS  PubMed  Google Scholar 

  72. Thunell S, Harper P, Brock A, Petersen NE (2000) Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. Scand J Clin Lab Invest 60:541–559

    Article  CAS  PubMed  Google Scholar 

  73. Utz N, Kinkel B, Hedde JP, Bewermeyer H (2001) MR imaging of acute intermittent porphyria mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology 43:1059–1062

    Google Scholar 

  74. Waldenstrom J (1957) The porphyrias as inborn errors of metabolism. Am J Med 22:758–773

    Article  CAS  PubMed  Google Scholar 

  75. Watson CJ, Taddeini L, Bossemaier I (1964) Present Status of the Ehrlich Aldehyde Reaction for Urinary Porphobilinogen. JAMA 190:501–504

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. C. Bollheimer.

Additional information

Serie: Die Notfall- und Intensivtherapie bei endokrinen und metabolischen Erkrankungen Herausgegeben von J. Schölmerich und U. Woenckhaus (Regensburg)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bollheimer, L.C., Reng, C.M. Die akuten hepatischen Porphyrien in der Notfall- und Intensivmedizin. Intensivmed 41, 388–405 (2004). https://doi.org/10.1007/s00390-004-0478-4

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00390-004-0478-4

Key words

Schlüsselwörter

Navigation